Orbimed Advisors LLC Essa Pharma Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.65 - $3.31 $210,871 - $263,389	-79,574 Reduced 8.63%	842,366 $2.6 Million
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.34 $718,632 - $923,165	-276,397 Reduced 23.07%	921,940 $2.49 Million
Q1 2023 May 15, 2023	BUY	$2.56 - $3.55 $2.13 Million - $2.96 Million	833,037 Added 228.04%	1,198,337 $3.56 Million
Q4 2022 Feb 14, 2023	SELL	$1.5 - $4.82 $413,017 - $1.33 Million	-275,345 Reduced 42.98%	365,300 $920,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.44 $1.12 Million - $2.2 Million	640,645 New	640,645 $1.17 Million
Q1 2021 May 17, 2021	SELL	$11.61 - $32.08 $5.35 Million - $14.8 Million	-460,500 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.47 - $12.1 $3.92 Million - $8.68 Million	-716,983 Reduced 60.89%	460,500 $5.49 Million
Q3 2020 Nov 16, 2020	SELL	$6.0 - $7.79 $1.77 Million - $2.29 Million	-294,370 Reduced 20.0%	1,177,483 $8.13 Million
Q3 2019 Nov 14, 2019	BUY	$1.46 - $3.37 $2.15 Million - $4.96 Million	1,471,853 New	1,471,853 $4.96 Million

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $72.3M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.